Movatterモバイル変換


[0]ホーム

URL:


AR044774A1 - ATORVASTATIN PHARMACEUTICAL COMPOSITIONS - Google Patents

ATORVASTATIN PHARMACEUTICAL COMPOSITIONS

Info

Publication number
AR044774A1
AR044774A1ARP040102008AARP040102008AAR044774A1AR 044774 A1AR044774 A1AR 044774A1AR P040102008 AARP040102008 AAR P040102008AAR P040102008 AARP040102008 AAR P040102008AAR 044774 A1AR044774 A1AR 044774A1
Authority
AR
Argentina
Prior art keywords
atorvastatin
compositions
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
Prior art date
Application number
ARP040102008A
Other languages
Spanish (es)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert CofiledCriticalWarner Lambert Co
Publication of AR044774A1publicationCriticalpatent/AR044774A1/en

Links

Classifications

Landscapes

Abstract

Translated fromSpanish

Una composición farmacéutica granulada en húmedo que comprende atorvastatina o una de sus sales farmacéuticamente aceptables con menos de aproximadamente 5 % en peso de un aditivo constituido por una sal de metal alcalino-térreo con un desintegrante, que proporciona la atorvastatina con no más de aproximadamente 3 % de lactona de atorvastatina, basada en la relación del área del pico de lactona comparada con las áreas integradas de todos los picos relacionados con el fármaco, así como dicha composición farmacéutica granulada en húmedo que comprende atorvastatina o una de sus sales farmacéuticamente aceptables en combinación con al menos otro fármaco activo, métodos para preparar dichas composiciones, kits para contener dichas composiciones, y un método de tratar hipercolesterolemia y/o hiperlipidemia, osteoporosis, hiperplasia prostática benigna (BPH), y la enfermedad de Alzheimer que comprende una cantidad terapéuticamente eficaz de las composiciones farmacéuticas.A wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof with less than about 5% by weight of an additive consisting of an alkaline earth metal salt with a disintegrant, which provides atorvastatin with no more than about 3 % of atorvastatin lactone, based on the ratio of the area of the lactone peak compared to the integrated areas of all drug-related peaks, as well as said wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing said compositions, and a method of treating hypercholesterolemia and / or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease comprising a therapeutically effective amount of the pharmaceutical compositions s.

ARP040102008A2003-06-122004-06-10 ATORVASTATIN PHARMACEUTICAL COMPOSITIONSAR044774A1 (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US47811903P2003-06-122003-06-12

Publications (1)

Publication NumberPublication Date
AR044774A1true AR044774A1 (en)2005-10-05

Family

ID=33551806

Family Applications (1)

Application NumberTitlePriority DateFiling Date
ARP040102008AAR044774A1 (en)2003-06-122004-06-10 ATORVASTATIN PHARMACEUTICAL COMPOSITIONS

Country Status (15)

CountryLink
EP (1)EP1635814A1 (en)
JP (1)JP2006527260A (en)
KR (1)KR100814218B1 (en)
CN (1)CN100434069C (en)
AR (1)AR044774A1 (en)
AU (1)AU2004246868B2 (en)
BR (1)BRPI0411344A (en)
CA (1)CA2465565A1 (en)
CO (1)CO5650230A2 (en)
MX (1)MXPA05013281A (en)
NO (1)NO20060022L (en)
NZ (1)NZ543337A (en)
RU (1)RU2332211C2 (en)
TW (1)TW200503690A (en)
WO (1)WO2004110431A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
FI94339C (en)1989-07-211995-08-25Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
GB0613925D0 (en)*2006-07-132006-08-23Unilever PlcImprovements relating to nanodispersions
US20100196469A1 (en)*2007-06-252010-08-05Pharmathen S.A.Pharmaceutical Formulation containing an HMG-COA Reductase Inhibitor and method for the preparation thereof
JP5492790B2 (en)*2008-02-272014-05-14トーメン メディカル アーゲー Implant and manufacturing method thereof
JP5714492B2 (en)*2008-09-172015-05-07マイラン インコーポレイテッド Granules, methods for their preparation, and pharmaceuticals containing them
RU2404767C1 (en)*2009-08-112010-11-27Закрытое Акционерное Общество "БИОКОМ"Solid dosage form having hypolipidemic and hypocholesteremic activity, and method of its production
HUP1000299A2 (en)2010-06-082012-02-28Nanoform Cardiovascular Therapeutics LtdNanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation
EP2779999A2 (en)2011-11-152014-09-24Dr. Reddy's Laboratories Ltd.Pharmaceutical formulations comprising atorvastatin and glimepiride
UA117464C2 (en)*2012-11-022018-08-10Вертекс Фармасьютікалз Інкорпорейтед PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CFTR DISEASE-MEDIATED DISEASE REGULATOR
CN104069078B (en)*2014-05-222019-06-11西藏九瑞健康股份有限公司 Atorvastatin calcium pharmaceutical composition and preparation method thereof
EA202191301A1 (en)*2014-07-252021-11-30Новартис Аг COMPOSITION OF TABLETS 2-FLUORO-N-METHYL-4- [7- (QUINOLIN-6-YLMETHYL) IMIDAZO [1,2-b] [1,2,4] TRIAZIN-2-YL] BENZAMIDE
KR101658350B1 (en)*2015-02-062016-09-30경성대학교 산학협력단Pharmaceutical Composition For Treating Hyperlipidaemia
CN107427462B (en)*2015-03-122023-08-29杜邦营养美国有限公司solid dispersion
EP3437646A4 (en)2016-03-312019-11-27Intercept Pharmaceuticals, Inc. ORAL PREPARATION HAVING EXCEPTIONAL ABILITY TO ELUTE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DK0680320T3 (en)*1993-01-191999-10-25Warner Lambert Co Stable oral CI-981 preparation and method of preparation thereof
JPH06242003A (en)*1993-02-121994-09-02Nkk CorpGrain size measuring method for alumina in steel
JP3014040B2 (en)*1996-10-302000-02-28信久 川野 Dietary fiber bread and method for producing the same
IL152179A (en)*2000-04-102009-06-15Teva PharmaStable pharmaceutical compositions containing 7-substituted-3,5- dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6242003B1 (en)*2000-04-132001-06-05Novartis AgOrganic compounds
EP1226818A1 (en)*2001-01-262002-07-31Pfizer Products Inc.Pharmaceutical dosage forms with enhanced cohesive and compressibility properties
SI20848A (en)*2001-03-142002-10-31Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D.Pharmaceutical formulation containing atorvastatin calcium
EP1291017A3 (en)*2001-09-102003-07-02Warner-Lambert CompanyUse of statins to inhibit formation of osteoclasts

Also Published As

Publication numberPublication date
KR20060020666A (en)2006-03-06
NZ543337A (en)2008-03-28
WO2004110431A1 (en)2004-12-23
CA2465565A1 (en)2004-12-12
RU2332211C2 (en)2008-08-27
NO20060022L (en)2006-01-03
CN1805741A (en)2006-07-19
JP2006527260A (en)2006-11-30
TW200503690A (en)2005-02-01
BRPI0411344A (en)2006-07-11
KR100814218B1 (en)2008-03-17
MXPA05013281A (en)2006-03-09
CN100434069C (en)2008-11-19
AU2004246868B2 (en)2008-01-17
RU2005136745A (en)2006-07-27
CO5650230A2 (en)2006-06-30
EP1635814A1 (en)2006-03-22
AU2004246868A1 (en)2004-12-23

Similar Documents

PublicationPublication DateTitle
AR044774A1 (en) ATORVASTATIN PHARMACEUTICAL COMPOSITIONS
AR044775A1 (en) ATORVASTATIN PHARMACEUTICAL COMPOSITIONS
DK1346041T3 (en) Therapeutic agents and methods for their use in the treatment of an amyloidogenic disease
LU93078I2 (en) COMBIMETINIB, POSSIBLY IN ANY FORM PROTECTED BY THE BASIC PATENT, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS AND SOLVATES, IN PARTICULAR COBIMETINIB HEMIFUMARATE
ES2124372T3 (en) COMPOSITIONS OF PROLONGED RELEASE BASED ON MORPHINE.
GT200100137A (en) PRO-DRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES.
NO20060149L (en) Pharmaceutical compounds of atorvastatin
EA200901393A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENES AND / OR ESTROGENS AND 5 METHYL- (6S) -TETRAHYDROPHOLATE
ATE360630T1 (en) AZABICYCLIC HETEROCYCLES AS MODULATORS OF THE CANNABINOID RECEPTOR
CR8102A (en) DERIVATIVES OF PIRAZOLO-QUINAZOLINA, PROCEDURE FOR PREPARATION AND ITS USE AS QUINASE INHIBITORS
GT200500098A (en) NEW COMPOUNDS
AR058780A1 (en) IMIDAZOPIRAZINAS AS INHIBITORS OF CYCLINE-DEPENDENT KINASES
UY30377A1 (en) FUSIONATED TRICYCLE INHIBITORS OF SULFONAMIDE OF GAMA-SECRETASA
PA8606201A1 (en) PIRROLO DERIVATIVES [3,4-c) PIRAZOL ASSETS AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
AR060019A1 (en) PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER
BRPI0509074A (en) pharmaceutical compositions comprising thyroid receptor agonists
AR048336A1 (en) HYDROCLORIDE OF (4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL) - (4-BROMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
MX2024013019A (en)Heteroaryl compounds for the treatment of pain
AR018162A1 (en) SUBSTITUTED PIRROLS, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION
AR030140A1 (en) COMPOSITIONS DERIVED FROM 2-PYRIDINAMINE AND RELATED METHODS
SE0401655D0 (en) New compounds
AR026911A1 (en) PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF TUMOR AFFECTIONS
DK1784173T3 (en) Pharmaceutical composition for the prevention and treatment of metabolic bone disorders containing alpha-arylmethoxyacrylate derivatives
EA200401100A1 (en) 1α-FTOR-25-HYDROXY-16,23E-DIEN-26,27-BISHOMO-20-EPICHOLOCALTI-SPHEROL AND ITS APPLICATION FOR TREATMENT
AR040121A1 (en) A COMBINATION OF NMDA ANTAGONIST AND INHIBITORS OF ACETILCOLINE ESTERASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Legal Events

DateCodeTitleDescription
FBSuspension of granting procedure

[8]ページ先頭

©2009-2025 Movatter.jp